spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

Former X CEO Yaccarino takes helm at digital health company eMed

Weight-loss focused digital company eMed Population Health on Tuesday named Linda Yaccarino, the former chief of Elon Musk’s social media platform X, as CEO.

The online weight management company’s digital platform provides at-home diagnostics, proctor-led screenings and physician-guided prescribing for patients with obesity and type 2 diabetes.

Yaccarino has virtually no experience in the health sector but brings more than a decade of advertising expertise. She led the modernization of NBCUniversal’s ad business and built major brand partnerships at the Comcast-owned company.

In her first public statement following her appointment, Yaccarino said, “There is an opportunity to combine technology, lifestyle, and data in a new powerful way through the digital channels that impact consumers directly in ways that have never been done before.”

At X, where she spent two years, Yaccarino was tasked with revitalizing the company’s reputation among marketers who had fled the platform after its takeover by Musk.

She stepped down from her role at the social media site in July, in a surprise move just months after the platform was acquired by the billionaire’s AI startup, xAI.

She did not give a reason for her departure from X, but analysts noted her task was a difficult one given Musk’s reputation and the more prominent placement of extreme content on X that had repelled some advertisers.

Hot this week

Daewoong Pharmaceutical Holds Talks with Saudi Officials on Bioindustry Cooperation

Daewoong Pharmaceutical said on October 17 that it met...

Novo Nordisk chair and independent directors to exit in strategy dispute

The chair of Wegovy maker Novo Nordisk and six...

Hologic to go private in up to $18.3 billion deal backed by Blackstone, TPG

Medical diagnostics firm Hologic has agreed to be acquired...

China’s Innovent signs $11.4 billion cancer therapy deal with Japan’s Takeda

-China’s Innovent Biologics said on Wednesday it had signed...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img